quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:06:10·57d
SECFiling
Catalyst Pharmaceuticals Inc. logo

SEC Form 10-K filed by Catalyst Pharmaceuticals Inc.

CPRX· Catalyst Pharmaceuticals Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • CPRX
    Catalyst Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Feb 4UpdateRobert W. Baird$28.00
  • Nov 18UpdateStephens$35.00
  • Mar 14UpdateCitigroup$27.00
  • Mar 7UpdateBofA Securities$23.00
  • Dec 21UpdateOppenheimer$30.00
  • Aug 24UpdateROTH Capital$15.50

Related

  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Catalyst Pharmaceuticals Inc.
  • SEC36d
    SEC Form 8-K filed by Catalyst Pharmaceuticals Inc.
  • PR48d
    Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
  • SEC57d
    SEC Form 8-K filed by Catalyst Pharmaceuticals Inc.
  • PR57d
    Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
  • PR58d
    Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
  • INSIDER63d
    Chief HR Officer Russo Gregg covered exercise/tax liability with 211 shares and converted options into 687 shares (SEC Form 4)
  • PR71d
    Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022